Portal de Periódicos da CAPES

CA 125 half‐life breakpoint between a “good” and “poor” prognosis in patients with ovarian cancer

2005; Elsevier BV; Volume: 88; Issue: 3 Linguagem: Inglês

10.1016/j.ijgo.2004.12.028

1879-3479

A. Mano, Inês Fernandes Godinho, Amílcar Falcão,

Endometrial and Cervical Cancer Treatments

International Journal of Gynecology & ObstetricsVolume 88, Issue 3 p. 333-335 Brief communications CA 125 half-life breakpoint between a “good” and “poor” prognosis in patients with ovarian cancer A. Mano, A. Mano Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, 3000-295 Coimbra, PortugalSearch for more papers by this authorI. Godinho, I. Godinho Gynaecology Service, Coimbra University Hospital, Coimbra, PortugalSearch for more papers by this authorA.C. Falcão, Corresponding Author A.C. Falcão [email protected] Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, 3000-295 Coimbra, PortugalCorresponding author. Tel.: +351 239 855092; fax: +351 239 855099.Search for more papers by this author A. Mano, A. Mano Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, 3000-295 Coimbra, PortugalSearch for more papers by this authorI. Godinho, I. Godinho Gynaecology Service, Coimbra University Hospital, Coimbra, PortugalSearch for more papers by this authorA.C. Falcão, Corresponding Author A.C. Falcão [email protected] Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, 3000-295 Coimbra, PortugalCorresponding author. Tel.: +351 239 855092; fax: +351 239 855099.Search for more papers by this author First published: 22 January 2005 https://doi.org/10.1016/j.ijgo.2004.12.028Citations: 7Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References [1]Baker V.V. Treatment options for ovarian cancer. Clin. Obstet. Gynaecol. 44(3): 2001; 522–530 10.1097/00003081-200109000-00007 PubMedWeb of Science®Google Scholar [2]Bast R.C. Jr., Xu F.J., Yu Y.H., Barnhill S., Zhang Z., Mills G.B. CA 125: the past and the future. Int. J. Biol. Markers. 13(4): 1998; 179–187 PubMedWeb of Science®Google Scholar [3]Bidart J.M., Thuillier F., Augereau C., Chalas J., Daver A., Jacob N., et al. Kinetic of serum marker concentrations and usefulness in clinical monitoring. Clin. Chem. 45(10): 1999; 1695–1707 PubMedWeb of Science®Google Scholar [4]Čolaković S., Lukiç V., Mitroviç L., Jeliç S., Šušnjar S., Marinkoviç J. Prognostic value of CA 125 kinetics and half-life in advanced ovarian cancer. Int. J. Biol. Markers. 15(2): 2000; 147–152 PubMedWeb of Science®Google Scholar Citing Literature Volume88, Issue3March 2005Pages 333-335 ReferencesRelatedInformation